@mallyroncal's HRT update claims need more context

What did @mallyroncal actually say?

Mally Roncal documented a real-world hormone therapy adjustment: she started on a testosterone patch at 0.25 mg, developed a contact rash, switched to a 0.25 mg gel, found that dose insufficient, and moved up to 0.5 mg gel with good results. She described early gel application as feeling "a little sunburny" before her skin adjusted. She's not making dramatic health claims here. She's sharing a personal titration experience, which is actually more responsible than most hormone content on Instagram.

The video is categorized under TRT, and that's accurate. Low-dose testosterone therapy for women, particularly post-menopausal women over 50, is a legitimate clinical practice, though it remains off-label in the United States. Roncal doesn't name a specific product brand, doesn't recommend doses for viewers, and points people toward their own providers. That restraint matters in this space.

Does the science back this up?

Yes, most of it. Patch-related contact dermatitis is a documented and common reason women discontinue testosterone patches. The switch to gel is a clinically recognized workaround, and transdermal gels generally produce more consistent serum levels with lower irritation rates for most users.

The 0.25 mg to 0.5 mg dose range she describes sits within the low-end spectrum discussed in clinical literature on female testosterone therapy. Davis et al. (2019, The Lancet Diabetes and Endocrinology) published a systematic review and consensus position statement finding that testosterone therapy improves sexual function in postmenopausal women, with transdermal delivery being the preferred route for its predictable absorption profile. The authors noted that doses producing physiological female testosterone levels, roughly 150-300 pg/mL serum total testosterone, are associated with benefit and acceptable safety in the short to medium term.

Rotating application sites, as Roncal describes doing between inner thighs, is consistent with prescribing guidance to reduce localized skin reactions. The "sunburny" sensation she mentions is a recognized mild local reaction to alcohol-based gel carriers, typically resolving within two to four weeks of regular use.

What did they get wrong (or right)?

Roncal gets more right than wrong here. The clinical sequencing she describes, patch to gel, dose adjustment based on response, site rotation, matches how this therapy is actually managed. She doesn't claim testosterone fixed her mood, her metabolism, or her skin. She stays in her lane.

What's missing is context about monitoring. She doesn't mention bloodwork, and that omission matters. Female testosterone therapy requires periodic serum testosterone and hematocrit monitoring to avoid supraphysiologic levels, which carry androgenic side effects including acne, hair thinning, and voice changes. Glaser and Dimitrakakis (2013, Maturitas) documented that without monitoring, women on testosterone therapy can drift into supraphysiologic ranges without recognizing early warning signs.

To be fair, this is a short update video, not a medical tutorial. But the audience is clearly taking notes on doses and methods. A single sentence about "your doctor will check your levels" would have added meaningful safety framing without changing the tone of the post.

What should you actually know?

Testosterone therapy for women is real, studied, and for some postmenopausal women, clinically meaningful, particularly for hypoactive sexual desire disorder. But it is off-label in the US, meaning no FDA-approved testosterone product exists specifically for women. Most prescriptions are written for compounded formulations or male products used at fractions of the standard male dose.

That off-label status doesn't make it dangerous, but it does mean:

• Formulation quality varies significantly between compounding pharmacies.
• Dosing guidance is extrapolated from research, not FDA-approved labeling.
• Insurance rarely covers it, and cost varies widely.
• Long-term cardiovascular and breast tissue data beyond two years remains limited.

If you're considering this therapy, the Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Wierman et al., 2014, Journal of Clinical Endocrinology and Metabolism) remains the most cited framework. It recommends therapy only after a thorough hormonal workup and with baseline and follow-up serum testing every six to twelve months. "Starting" based on a social media video without that workup is the part that can go sideways.

Roncal's experience is legitimate. Her telling it publicly isn't the problem. The problem is when viewers treat her dose numbers as a starting prescription for themselves.